



Immunocore announces dosing of first patient with third ImmTAC® bispecific

December 9, 2019

Immunocore announces dosing of first patient with third ImmTAC® bispecific

IMC-C103C studied in various MAGE-A4 expressing solid tumours

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 December 2019)

Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announced the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the company's innovative ImmTAC® technology platform. IMC-C103C is focused on targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4) and is being developed in partnership with Genentech, a member of the Roche Group.

The trial (IMC-C103C-101) is designed to study the safety and preliminary activity of IMC-C103C as a monotherapy and in combination with atezolizumab (Tecentriq®) in patients with MAGE-A4-expressing cancers.

David Berman, Head of Research and Development at Immunocore, commented: "We have now brought our third TCR- engineered bispecific ImmTAC into the clinic. IMC-C103C is designed to re-direct T cells to attack MAGE-A4 expressing tumours and we're pleased to be moving its clinical development forward in partnership with Genentech."